Table 1.
Demographics, clinical characteristics and outcomes of 62 episodes of left-sided MSSA IE treated with β-lactams according to high or low vancomycin MIC
| Characteristic | Vancomycin MIC <1.5 μg/mL (n = 28) | Vancomycin MIC ≥1.5 μg/mL (n = 34) | p |
|---|---|---|---|
| Age, years, mean (SD) | 61.1 (18.5) | 60.1 (14.3) | 0.396 |
| Male gender, n (%) | 19 (68%) | 27 (79%) | 0.386 |
| Type of endocarditis | 0.548 | ||
| Native valve | 23 (82%) | 25 (74%) | |
| Prosthetic valve | 5 (19%) | 9 (27%) | |
| Origin of acquisition | 0.916 | ||
| Community acquired | 17 (61%) | 23 (68%) | |
| Nosocomial | 8 (29%) | 9 (26%) | |
| Healthcare related | 2 (7%) | 2 (6%) | |
| Unknown | 1 (3%) | 0 | |
| Geographic area | 0.333 | ||
| North America | 4 (14%) | 10 (29%) | |
| Europe/Mideast | 20 (71%) | 22 (65%) | |
| South America | 1 (4%) | 0 | |
| Australia/New Zealand | 3 (11%) | 2 (6%) | |
| Complications | |||
| Heart failure | 13 (46%) | 10 (29%) | 0.195 |
| Systemic emboli | 10 (36%) | 8 (23%) | 0.400 |
| Stroke | 7 (25%) | 9 (27%) | 1.000 |
| Paravalvular complications | 8 (29%) | 11 (32%) | 0.788 |
| New conduction abnormality | 0 (–) | 3 (9%) | 0.245 |
| Persistent bacteraemia | 4 (14%) | 4 (12%) | 1.000 |
| Surgical treatment | 9 (32%) | 14 (41%) | 0.599 |
| Relapsea | 0 | 0 | 1.000 |
| Mortality | |||
| In-hospital mortality | 9 (32%) | 9 (27%) | 0.780 |
| 1-year mortality | 12 (43%) | 10 (29%) | 0.298 |
IE, infective endocarditis; MIC, minimum inhibitory concentration; MSSA, methicillin-susceptible Staphylococcus aureus.
a
Defined as new episode of endocarditis due to the same microorganism that caused the first IE within next 12 months.